-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
BNT162b2 vaccine (Pfizer-BioNTech) active immunization is an effective means to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and severe disease, and has been used in 117 countries in the Americas, the United Kingdom, Europe, Africa, Asia and Oceania State approved
Immunization to prevent infection Recently, researchers examined the safety and efficacy of a booster shot of the BNT162b2 vaccine in people over 16 years of age
The BNT162b vaccine is 95.
BNT162b vaccine is 95.
Ten months after the completion of the second dose of BNT162b2 vaccination, the effectiveness of the vaccine in preventing infection after the third dose reached 95.
3%, and no new safety events occurred
.
Ten months after the completion of the second dose of BNT162b2 vaccination, the effectiveness of the vaccine in preventing infection after the third dose reached 95.
3%, and no new safety events occurred
.
Original Source:
Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.
Leave a comment here